SLIGHT IMPROVEMENT FOR ALCHEMIA

SLIGHT IMPROVEMENT FOR ALCHEMIA

 ALCHEMIA Limited (ASX:ACL) has recorded a $5.5 million loss for the half year to December 2013, despite positive clinical trials in oncology overseas.

The drug development company’s loss is an improvement from $5.9 million at this time last year.

Total income dropped to $5 million, down from $9.4 million in the previous period, which included a $4.5 million research and development tax incentive income.

Over the six month period, ACL reduced operating expenses and administrative costs and significantly increased net cash balances from $6.1 million to $16.4 million.

As part of the company’s commercial agreement with Dr Reddy’s Laboratories, there was a $4.7 million profit share in fondaparinux medication in the US.

ACL will continue to treat metatastic colorectal cancer patients in its Phase III HA-Irinotecan clinical study.

Transpacific boosts profit. Read here.

Get our daily business news

Sign up to our free email news updates.

Please tick to verify that you are not a robot

 

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Top tips for successful digital transformation
Partner Content
Digital transformation, when done well, can transform your organisation's operation...
Advertisement

Related Stories

Early-stage funding hits record high as mega-deals drop off

Early-stage funding hits record high as mega-deals drop off

Despite venture capital funding falling by a third for Australian s...

The Star hit with two more shareholder class actions

The Star hit with two more shareholder class actions

Law firms Phi Finney McDonald and Shine Lawyers (ASX: SHJ) have ser...

Owner of Betty's Burgers, Boost Juice returns to Australian hands at $350m valuation

Owner of Betty's Burgers, Boost Juice returns to Australian hands at $350m valuation

The parent company of Boost Juice is set to return to Australian ha...

Emyria, Little Green Pharma shares spike after TGA green light for MDMA and psilocybin

Emyria, Little Green Pharma shares spike after TGA green light for MDMA and psilocybin

Alternative medicines stocks are on a tear today as investors take ...